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Abstract
Background: Host-microbiome interactions (HMIs) are critical for the modulation of biological processes and are
associated with several diseases. Extensive HMI studies have generated large amounts of data. We propose that the
logical representation of the knowledge derived from these data and the standardized representation of
experimental variables and processes can foster integration of data and reproducibility of experiments and thereby
further HMI knowledge discovery.
Methods: Through a multi-institutional collaboration, a community-based Ontology of Host-Microbiome
Interactions (OHMI) was developed following the Open Biological/Biomedical Ontologies (OBO) Foundry principles.
As an OBO library ontology, OHMI leverages established ontologies to create logically structured representations of
(1) microbiomes, microbial taxonomy, host species, host anatomical entities, and HMIs under different conditions
and (2) associated study protocols and types of data analysis and experimental results.
Results: Aligned with the Basic Formal Ontology, OHMI comprises over 1000 terms, including terms imported from
more than 10 existing ontologies together with some 500 OHMI-specific terms. A specific OHMI design pattern was
generated to represent typical host-microbiome interaction studies. As one major OHMI use case, drawing on data
from over 50 peer-reviewed publications, we identified over 100 bacteria and fungi from the gut, oral cavity, skin,
and airway that are associated with six rheumatic diseases including rheumatoid arthritis. Our ontological study
identified new high-level microbiota taxonomical structures. Two microbiome-related competency questions were
also designed and addressed. We were also able to use OHMI to represent statistically significant results identified
from a large existing microbiome database data analysis.
Conclusion: OHMI represents entities and relations in the domain of HMIs. It supports shared knowledge
representation, data and metadata standardization and integration, and can be used in formulation of advanced
queries for purposes of data analysis.
Keywords: Microbiome, Host-microbiome interaction, Ontology, Ontology of host-microbiome interactions, OHMI,
Metadata, OBO Foundry, Rheumatic disease, Rheumatoid arthritis
Background
A microbiome is defined as a community of microbes
(for example, bacteria) found in a particular habitat (for
example, a human host) [1–3]. Microbiomes exist in and
on human and other hosts, where they are crucial for ac-
tive immunologic and physiological system development
[1, 4–6]. Research in host-microbiome interaction
(HMI) has accelerated significantly in the past decade, as
evidenced by the rise in the number of microbiome-
related publications indexed in PubMed (from 604 to
over 11,500 in the ten years since 2018). This growing
body of HMI studies and associated data pose signifi-
cant challenges. For example, it can be difficult for in-
vestigators to achieve reproducible results across
laboratories, and even more challenging to integrate data
systematically across studies. To facilitate advanced data
integration and knowledge discovery, several funding
sources now require that data generated from funded re-
search be structured to conform to the FAIR (Findable,
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Accessible, Interoperable, and Reusable) data principles
[7]. To support data FAIRness and experimental repro-
ducibility in HMI research, a strategy is needed to
standardize the representation of the entities involved in
HMI, including host and microbial organisms, microbial
locations, and environments. As in other research areas,
so also here: the lack of a comprehensive standardized
representation of these entities prevents integration and
systems-level analysis of the HMI data produced by dif-
ferent studies, laboratories and institutions.
An ontology is a human- and computer-interpretable
representation of the types, properties, and interrelation-
ships that exist in a particular domain [8]. Ontologies
allow semantically-based reasoning by computer sys-
tems, and enable people and machines to make mutually
supportive logical inferences. In biomedical research, on-
tologies have served for some 20 years as powerful tools
for data classification, representation of standards, con-
struction of knowledge bases, and enhanced search and
analysis. Several microbiology-related ontologies exist,
including the NCBI organismal classification (NCBI-
Taxon) [9], the Uberon multi-species anatomy ontology
(UBERON) [10] and the Environment Ontology (ENVO)
[11]. These ontologies permit standardized representa-
tion of, respectively, host and microbial organisms, ana-
tomic locations of microbes inside hosts, and
microbiome environments. The Ontology for Microbial
Phenotypes (OMP) standardizes phenotypic information
relating to microbes [12]. The Ontology of Prokaryotic
Phenotypic and Metabolic Characters (MicrO) covers
the attributes of prokaryotes, the processes in which they
participate, and the material entities (such as cell com-
ponents, microbiological culture media and medium in-
gredients) with which they are associated in these
processes [13]. Many of the terms in OMP and MicrO
were themselves imported from existing OBO ontol-
ogies, including the Phenotypic Quality Ontology
(PATO) [14], the Gene Ontology (GO) [15], Chemical
Entities of Biological Interest (ChEBI) [16], the Protein
Ontology (PR) [17], and the Ontology for Biomedical In-
vestigations (OBI) [18].
The above-mentioned ontologies provide components
for the systematic representation of certain aspects of
HMIs, but they do not cover, for example, HMIs – the
interactions between hosts and microbiomes – them-
selves. They also do not cover the associations between
HMIs and specific diseases (such as rheumatoid arth-
ritis), or HMI investigation metadata. We have created
the Ontology of Host-Microbiome Interactions
(OHMI), therefore, not merely in order to incorporate
terms in these specific areas, which are important foci
of current microbiome research, but also to provide a
single framework for systematic representation of all
entities relevant to HMI.
Methods
OHMI ontology development
OHMI follows the Open Biological/Biomedical Ontologies
(OBO) Foundry (http://www.obofoundry.org/) principles.
For example, OHMI satisfies the openness and collabor-
ation principles [19], in that it is based on an open discus-
sion involving representatives from multiple disciplines
engaged in microbiome research in which not only the
scope of the ontology was identified but also the develop-
ment strategy, design patterns, and initial use cases. The
OHMI GitHub website (https://github.com/OHMI-ontol-
ogy/OHMI) documents the successive versions of the
ontology presented at the 23rd International Scientific
Symposium on Biometrics (BioStat 2017), the Sixth An-
nual Workshop of the Clinical and Translational Science
Ontology Group, and the Microbe 2018 meeting of the
American Society of Microbiology (ASM).
OHMI uses the eXtensible Ontology development
(XOD) methods [20], meaning that it reuses terms from
existing ontologies and aligns all terms within a single se-
mantic framework as defined by the Basic Formal Ontol-
ogy (BFO) [21]. The Ontofox tool was used for extraction
and reuse of terms from existing ontologies [22]. The
Ontorat tool was used for generating new terms based on
consensus ontology design patterns [23]. OHMI was for-
matted in the Web Ontology Language (OWL2), and the
Protégé OWL Editor (version 5.0) [24] was used for man-
ual editing. The HermiT reasoner (http://hermit-reasoner.
com/) tool was employed to detect inconsistencies or con-
flicts arising during development.
Host-microbiome interaction minimal information
collection and ontological representation
All HMI-related data elements were first compiled in a
spreadsheet from the literature, public resources, and
use cases, then discussed by the community, and trans-
formed into terms and relational expressions for inclu-
sion in the ontology. Following the OBO Foundry
principle of reuse, wherever a term was already defined
in one or more existing ontologies (identified using
Ontobee [25]) we imported the term into OHMI using
what we deemed to be the most biologically accurate
definition. Otherwise, we created a new term, which was
either (1) included in OHMI or (2) suggested for inclu-
sion in an appropriate higher-level OBO Foundry ontol-
ogy in order to make it available for importing into
OHMI.
OHMI use case studies and evaluation
Our major use case was the study of the association
between microbiome profiles and rheumatic diseases.
Rheumatic diseases include conditions causing chronic,
often intermittent pain affecting the joints and/or con-
nective tissues such as rheumatoid arthritis (RA),
He et al. Journal of Biomedical Semantics           (2019) 10:25 Page 2 of 14
ankylosing spondylitis (AS), and systemic lupus erythema-
tosus (SLE). In this study, we manually curated published
rheumatic disease-related HMI data from peer-reviewed
publications.
We have also defined and used two competency questions
derived from the rheumatic disease use case to evaluate the
OHMI ontology. For this purpose, we used the Simple
Protocol And Resource Description Framework (RDF)
Query Language (SPARQL) and Description Logic (DL)
languages. SPARQL is a query language that retrieves data
stored in the RDF format [26]. SPARQL queries were per-
formed using the Ontobee’s SPARQL endpoint (http://www.
ontobee.org/sparql) [25]. The SPARQL scripts are provided
in the OHMI GitHub (https://raw.githubusercontent.com/
OHMI-ontology/OHMI/master/docs/SPARQL%20scripts.
txt). DL queries were performed using the Protégé 5.0 (beta
15) DL Query plugin as described in the Results section.
Ontology access and license
OHMI is an open source project maintained through
https://github.com/ohmi-ontology. The source code, in-
cluding development and release versions, is available at
https://github.com/ohmi-ontology/OHMI. OHMI is re-
leased under a Creative Commons 4.0 License. It has
been accepted as an OBO library ontology (http://obo-
foundry.org/ontology/ohmi.html) and deposited in the
Ontobee ontology server [25] at http://www.ontobee.
org/ontology/OHMI, and in BioPortal [27] at https://
bioportal.bioontology.org/ontologies/OHMI. Ontobee is
the default server for dereferencing OHMI terms.
Results
OHMI ontology design and upper-level structure
Figure 1 shows selected upper-level terms and branches
of the OHMI hierarchy. Instead of coding everything
from scratch, we imported and aligned related terms
from existing reference ontologies in the OBO Library,
including BFO, NCBITaxon, ENVO, UBERON, OBI, and
the Information Artifact Ontology (IAO) [10].
The class OHMI: microbiome is defined as a subclass
of ENVO:biome. The latter is defined as follows:
biome = def. an ecosystem to which resident ecological
communities have evolved adaptations.
OHMI then defines microbiome as follows:
microbiome = def. a biome that consists of a collection
of microorganisms (i.e., microbiota) and the surround-
ing environment where the microorganisms reside and
have evolved adaptations.
OHMI further defines the term ‘microbiota’ as a sub-
class of the term ‘collection of organisms’ in the Popu-
lation and Community Ontology (PCO):
microbiota = def. a collection of microbial organisms
that reside in a particular environment.
Fig. 1 Selected upper level terms and hierarchy of OHMI. OHMI terms are marked by red labels. The full names of listed ontologies are provided
in the list of abbreviations at the end of this paper
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To define the ‘host’ class in OHMI, we first of all de-
fine the host role, which is a BFO:role borne by an entity
when one or more further entities are spatially located
in its interior. An OHMI:host is then an organism that
bears a host role in relation to some microbiome.
The basic design pattern of OHMI is illustrated in Fig. 2.
An ontology design pattern is a general pattern to solve a
recurrent modeling problem in ontology development by
providing scalable and robust representations of entities
and entity relations of a certain sort [23]. Terms from the
Relation Ontology (RO) [28] have been used to represent
OHMI assertions and to formulate corresponding defini-
tions. Specifically, a host-microbiome interaction (HMI) is
defined as follows:
host-microbiome interaction = def. an interaction that
occurs between a microbiome and its host.
with a logically equivalent class definition as follows:
host-microbiome interaction: interaction and (‘has partici-
pant’ some host) and (‘has participant’ some microbiome).
Each HMI occurs in some specific anatomic entity (for
example the gut) located in the host organism. This host
organism may in addition have a disease – a phenomenon
that is illustrated by the representation of a general HMI
pattern in patients with ankylosing spondylitis (AS) (Fig.
2). In this example, ‘AS human-gut microbiota interaction’
is a HMI in which the host is a human with AS, while
‘gut’ is the anatomic entity where the microbiota resides.
The ‘expansion of Porphyromonas macacae in AS human
gut’ is an ‘AS human-gut microbiota interaction’ in which
the size of the population of Porphyromonas macacae is
increased (Fig. 2).
As of September 9, 2019, OHMI contains 1238 terms, in-
cluding 1020 classes, and 128 object properties. OHMI in-
cludes 481 OHMI-specific classes and properties with the
“OHMI_” prefix, which are new ontology terms not cov-
ered in any other OBO Foundry ontologies. More detailed
and updated OHMI statistics can be found at the Ontobee
statistics page at: http://www.ontobee.org/ontostat/OHMI.
Systematic collection and representation of rheumatic
disease-related HMI knowledge
As a major use case, we systematically collected and an-
notated the peer-reviewed results of studies of HMI re-
lated to rheumatic diseases. Rheumatic diseases are
characterized by inflammation of connective tissues,
most commonly the joints, but also the tendons, liga-
ments, bones, muscles, and even solid organs. Our use
case study focused on the most common rheumatic dis-
eases, including AS, enthesitis-related arthritis (ERA),
gout, psoriatic arthritis (PsA), RA, and systemic lupus er-
ythematosus (SLE), which affect approximately 1% of the
global human population. RA is a common rheumatic
Fig. 2 Illustration of OHMI ontology design pattern for representing host-microbiome interactions. The red box represents different levels of host-
microbiome interactions. A specific example is the OHMI representation of a human-microbiome interaction in which the human host has the
disease ankylosing spondylitis (AS). The human and microbiome classes are duplicated in this figure for clarity. Note that not every organism has
the ‘host role’, and the role is here assigned to a host organism only in the case of host-microbiome interactions
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disease characterized by persistent synovitis, systemic in-
flammation, and autoantibodies [29]. Many studies have
found close associations between rheumatic diseases and
HMI [30–33]. Specifically, the gastrointestinal microbiome
and its homeostasis are altered in patients with autoimmune
and inflammatory rheumatic diseases such as RA [33, 34].
A significant amount of research on the role of the micro-
biome in autoimmunity has focused primarily on RA [35].
To better understand the relations among rheumatic
diseases and microbiomes, we performed a meta-analysis
of such relations from relevant literature. In total, from
52 papers (Additional file 2), we found references to 138
bacteria and fungus from the gut, oral cavity, skin, and
airway that are associated with the six rheumatic dis-
eases listed above. As an example, the review article by
Rosenbaum and Asquith [36] described how microbiome
components such as Prevotella copri, Porphyromonas
gingivalis, and Collinsella are expanded or depleted in
anatomical locations such as the gut, mouth, lung, and
skin in the patients of rheumatic diseases, and the
possible underlying mechanisms. These microbe-
rheumatic disease associations were represented in the
OHMI using the design pattern described above (Fig. 2).
Our meta-analysis identified increased or decreased mi-
crobe populations in patients with different types of
rheumatic diseases (Additional file 2).
OHMI can also represent specific types of bacteria that
are increased in population size in the intestinal micro-
biota in at least two rheumatic diseases compared to
healthy control (Fig. 3). Fifteen different bacterial cat-
egories that are enriched in human patients of different
rheumatic diseases (Fig. 3a, Additional file 2). Interest-
ingly the phylum Bacteroidetes includes 10 out of the 15
bacterial species increased in human rheumatic patients.
In comparison, only five bacterial categories are de-
creased in human patients with rheumatic diseases (Fig.
3b). Lachnospiraceae is increased in AS and SLE patients
[37, 38] (Fig. 3a), but decreased in ERA and gout pa-
tients [39, 40] (Fig. 3b). Coprococcus and Pseudobutyrivi-
brio, two bacteria types within Lachnospiraceae, were
Fig. 3 Ontological representation of the bacteria populations increased in the guts of patients with at least two different rheumatic diseases as compared
with healthy controls. (a) Bacterial population increased in patient guts. (b) Bacterial population decreased in patient guts. Many increased and decreased
bacterial populations are within the same genus. The red and blue circles represent increased and decreased profiles, respectively. Taxonomy terms
without circle and label are used to generate ontological hierarchies
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also found to be depleted in rheumatic diseases PsA [41]
and gout [39, 41], and SLE [42].
OHMI representation of key terms in an HMI investigation
A good representative example of the many studies on
host-microbiome interactions is the study of the inter-
action between rheumatic arthritis and human micro-
biome documented in [43]. In this study, samples were
collected from patients before or after antibiotic treat-
ment, and the diversity and composition of the respect-
ive microbiome constitutions were identified via 16S
rRNA gene sequencing. This study set out to address
three key HMI questions: (i) how do healthy and RA pa-
tients differ in the compositions of their microbiome?
(ii) does the composition of the microbiome in RA pa-
tients shift as a result of antibiotic treatment? and (iii)
are distinct clinical parameters in RA patients (e.g., auto-
antibody profiles) associated with distinct microbial
community profiles? Analogues of these three questions
appear in many microbiome studies across human,
animal and environmental disciplines.
To annotate a HMI study as illustrated above [43], we
draw on the general OHMI design pattern (Fig. 4). Ba-
sically, an HMI investigation involves the collection and
analysis of microbiome specimens from an anatomical
location in a host organism. The host organism will
have a certain demographic profile (sex, age and so
forth). It may be either a patient with a specific disease
or a healthy control. It may be treated with different in-
terventions, and the samples can be collected at differ-
ent time points subsequent to the medical intervention.
The processed samples are assayed, generating different
datasets. Conclusions can then be drawn on the basis of
the statistical analysis of these datasets.
The investigation of OHMI host-microbiome interactions
involves the representation of various metadata (i.e., “data
about data”) types. To standardize these, we reference dif-
ferent resources, starting with the Minimum Information
about a Genome Sequence (MIGS) [44] and about any (‘x’)
Sequence (MIxS) checklists [45]. While the latter specifies
the variables and the information required to describe a
genome sequence or any sequence, they do not cover all
the information about HMIs and they do not specifically
use ontologies. The metadata types documented in these
checklist resources were complemented by specific meta-
data types used in the studies recorded in the peer-
reviewed publications such as [43, 46, 47]. These metadata
types can be matched to entities defined in ontology.
Table 1 lists a representative minimal checklist of en-
tities that are important for representing an HMI investi-
gation. These terms cover various areas such as host,
microbiome sample extraction and analysis, host treat-
ment, and microbiome profile changes. These terms are
matched to the metadata types collected for HMI investi-
gation studies. OHMI has imported many corresponding
terms from existing ontologies. We also generated many
OHMI-specific terms for representation of host-pathogen
interactions (Table 1). As a result, OHMI allows us to
standardize the representation of a broad range of HMI
experiments, and to do this in a way that leads to more
advanced integrative data/metadata analyses of such stud-
ies, including analyses relating to sequence and other data.
Addressing competency questions using OHMI
In addition to the above-mentioned use case of rheum-
atic disease-associated HMI representation, we also ap-
plied OHMI to address several real-life competency
questions in additional use cases.
Fig. 4 OHMI design pattern of key entities important for HMI investigation. Note that not every organism has the ‘host role’, and the role is here
assigned to a host organism only in the case of host-microbiome interaction
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Competency question 1: What are the human
diseases for which a bacterium or bacterial group
(for example, E. coli) is expanded in population size
in the microbiome?
A commonly asked competency question relates to the
identification of the microbiome components that are
increased in humans with a specific disease as compared
with healthy control subjects. For example, Porphyromo-
nas macacae is expanded in the gut of AS patients,
which we represent by means of the term ‘expansion of
Porphyromonas macacae in AS human gut’ (Fig. 2). This
OHMI relationship between the HMI and the bacterium
Porphyromonas macacae is here represented as:
‘expansion of Porphyromonas macacae in AS human
gut’: ‘has microbe expanded in diseased host’ some
‘Porphyromonas macacae’.
The relational expression ‘has microbe expanded in dis-
eased host’ is an object property that represents the rela-
tion between a host-microbiome interaction (HMI) and a
microbe, where the population of the microbe is expanded
in a diseased host as compared to a healthy host control.
As illustrated in the above example, the domain of the re-
lation is a HMI process, and the range is a microbe such
as a bacterium. This specific relation is formulated in nat-
ural language by means of several different expressions.
The inclusion of such a specific relation in OHMI pro-
vides a single target for the corresponding annotations
which represents a direct logical linkage between a
disease-specific HMI and a microbe. OHMI thereby sup-
ports efficient knowledge querying and analysis also where
we take natural-language inputs as our starting point.
We can use the relationship ‘has microbe expanded in
diseased host’ to represent the disease-associated HMIs
related to each specific bacterium or bacterium group.
For example, such a representation method can be used
to identify all the E. coli-associated human diseases in-
vestigated in [48–51] on the basis of a single DL query,
using either Protégé (Fig. 5a) or the Ontobee SPARQL
endpoint (Fig. 5). The same outcome was achieved using
either approach. The results indicate that E. coli and
four specific E. coli strains were found in rheumatic
arthritis, gout, and colorectal cancer.
Competency question 2: What microorganisms are
expanded or depleted in subjects with a specific
disease (for example RA) relative to health controls?
OHMI records manually mined knowledge relating to
many types of microorganisms that are increased or de-
creased in population size in patients with a specific disease
relative to healthy controls. This knowledge is often ob-
tained by text-mining all the papers referenced in the litera-
ture reports of well-controlled epidemiological studies.
OHMI represents this knowledge in two ways. First, it cre-
ates a logically well-defined representation of a specific
HMI in association with specific disease and microbiome
information, as exemplified in Fig. 2 and also shown below:
Table 1 Selected OHMI entities important for HMI investigation
Topics Example terms Ontology
Host host organism (e.g., human, rat); age, biological sex;
disease (e.g., RA, diarrhea); phenotype (e.g., obesity, diarrhea); host anatomical entity (e.g., mouth,
stomach); drug product; dysbiosis
NCBITaxon PATO
DOID MPO, HPO, …
UBERON DRON
OHMI
Microbe microbial taxonomy at various levels (e.g., E. coli);




Environment conditions environment (e.g., dwelling, wild field);
metabolite (e.g., iron, zinc and arginine), nutrition, …
ENVO CHEBI
Sample collection collection date/time, collection method, device;
geographic location
OBI GAZ
HMI samples sample from host, e.g., gut, oral, saliva;
sample from environment, e.g., soil, table surface
OBI ENVO
Assays RNA-seq, genome sequencing OBI
Statistical analyses ANOVA, t-test, Wilcoxon rank-sum test, MLG-based
classifier, KEGG analysis, metagenomic sequencing
data, p-value
OBCS
HMI results relative abundance of microbe in host, α-diversity,
differentially enriched bacterium (or gene) marker
for dysbiosis/disease, overgrowth vs. depletion
(or reduced growth); microbiome restoration by
treatment (e.g., antibiotics, DMARD)
OHMI (4–5)
The column ‘Ontology’ represents the source ontology in which the example terms are defined. All the terms are defined either in OHMI or imported from other
ontologies to OHMI
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‘expansion of Porphyromonas macacae in AS human
gut’: ‘has microbe expanded in diseased host’ some
(‘Porphyromonas macacae’ and (‘located in’ some
(‘lower digestive tract’ and (‘part of’ some (‘Homo sapi-
ens’ and (‘has disease’ some ‘ankylosing
spondylitis’)))))).
The above is a class definition formulated using logical
equivalence. It thus provides necessary and sufficient
conditions for the specific HMI class to be exemplified.
Using this type of definition, we can specify the link be-
tween the microbe P. macacae and the disease ankylos-
ing spondylitis (AS). This style of logical definition can
serve as a basis for both DL and SPARQL queries. How-
ever, since the logical definition includes four relations
and is quite complex, it is difficult to write efficient
query scripts for queries of this sort.
To solve this problem, OHMI provides shortcut rela-
tions to link an organism directly to a disease, for
Fig. 5 Query of diseases associated with increased E. coli in human gut. (a) DL query based on the host-pathogen interaction classifications; (b) SPARQL query
based on the linkage from organism to disease. The SPARQL query was conducted using the Ontobee SPARQL endpoint (http://www.ontobee.org/sparql)
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example, ‘has microbe depleted in gut of human with
disease’, which is used as follows:
Prevotella:
‘microbe susceptibly depleted in gut of human with
disease’ some ‘rheumatoid arthritis’.
From this we can easily generate DL or SPARQL query
scripts. For example, using a SPARQL query using the
above relation, we quickly identified 45 distinct bacterial
species that are associated with RA through six different
relationships (Additional file 1: Figure S1). These 45 species
can be organized using an ontological hierarchy (Fig. 6),
which reveals several interesting phenomena. For example,
both Lactobacillus sp. and Lactobacillus salivariusc are
increased in RA patients, the former in the gut, the latter
in the oral cavity. On the other hand, five bacteria under
Betaproteobacteria were all depleted in RA patients.
Among them, three Neisseriaceae bacterial groups (Eike-
nella, Kingella, and Neisseria spp.) are all decreased in the
oral cavity in the RA patients, two Burkholderiales groups
(Burkholderia and Sutterella wadsorthensis) are depleted in
the gut or respiratory airway of the RA patients. Interest-
ingly, Bifidobacterium bifidum is decreased in the gut of
RA patients; however, Bifidobacterium dentium is in-
creased (Fig. 6). These findings merit further investigation
to identify the underlying mechanisms associated with each
of these phenomena.
Discussion
This paper introduces the development and application
of a community-driven ontology to represent HMIs.
OHMI standardizes HMI-related terms and the relations
among them. The top level hierarchical structure and
general OHMI design pattern are described, followed by
descriptions of uses of OHMI with examples and com-
petency questions. OHMI was developed by following
best practices [8] and recommended strategies of ontol-
ogy reuse [7] and design pattern-based development
[23]. OHMI seamlessly integrates related terms from
existing ontologies with terms specifically related to
HMIs. Our use cases demonstrate that OHMI is useful
in HMI knowledge representation, data and metadata
standardization, and information query and analysis.
OHMI provides a consistent and hierarchical represen-
tation of the known HMIs, where the individual microbes,
anatomic locations, host species, and host qualities are
also represented using the ontology. As shown in the
rheumatic disease use case, we were able to identify those
expanded and depleted microbes associated with rheum-
atic diseases. The ontological classification of expanded
microbes suggests possible virulent factors and potential
pathogenesis in rheumatic diseases, whereas queries iden-
tifying depleted bacteria may identify potential candidates
for treatment with biological agents [52].
OHMI development is a community effort. For ex-
ample, OHMI was presented at the Sixth Annual Work-
shop of the Clinical and Translational Science Ontology
Group held in October of 2017 in Ann Arbor, Michigan,
USA [53]. The focus of this meeting was to introduce
different microbiology-related ontologies, including
OHMI, in order to better understand the type of
standardization needed to facilitate data integration.
There was a consensus that the OHMI and other
microbiology-related ontologies should be developed
and used by the community to support not only data
and knowledge integration but also the design of experi-
mental studies that would be reproducible.
Although the knowledge represented in OHMI is com-
monly obtained from review of published papers, we can
also analyze raw data and generate new information
about microbiome and relation examples from an exist-
ing database. MicrobiomeDB (http://microbiomedb.org)
is a web-based database and systems biology platform
for integrating, mining and analyzing data from micro-
biome experiments [46]. We used the platform to
search, analyze and compare microbiome profiles under
different conditions. For example, MicrobiomeDB col-
lected over 1000 samples used for study of diarrheal dis-
ease and the microbiome in children [54, 55]. Using the
dataset collected in MicrobiomeDB and the data analysis
tool in the database, we found that Prevotella is signifi-
cantly lower in diarrheal patients compared to controls;
however, for unclassified Proteobacteria and Natronoba-
cillus bacteria the converse was true (Fig. 7a). In addition
to the disease condition, age was also found to be a
major factor. Our MicrobiomeDB analysis found that
the amount of E. coli was low in the healthy state in the
guts of infants compared to children, but was signifi-
cantly higher in the infant gut during diarrhea than in
the healthy state. The results obtained from analysis of
the large MicrobiomeDB dataset can be semantically
represented using OHMI (Fig. 7b). This permits the
querying of MicrobiomeDB results together with other
information drawn from peer-reviewed results. Future
directions will include more analysis and representation
of MicrobiomeDB data in OHMI in order to improve
representation and understanding of HMI mechanisms.
Reproducibility of both experiments and data analyses
depends on consistent procedures employed across differ-
ent settings. OHMI harmonizes the metadata representa-
tion of the interactions between microbiomes and hosts
along with associated biological processes, supporting the
integration and systems-level analysis of HMI data pro-
duced by different laboratories and institutions. To support
reproducibility and advanced analysis, we plan to work with
the MicrobiomeDB project to support ontology-based data
standardization, browsing, and advanced analyses. Specific-
ally, MicrobiomeDB will use OHMI terms and metadata
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types to standardize the currently still highly heterogeneous
MicrobiomeDB data. The information captured in OHMI
can also provide prior knowledge that can be used to en-
hance queries and analyses of MicrobiomeDB data. One
such strategy is to allow users who have identified differen-
tially abundant taxa (using the existing differential abun-
dance app) to leverage OHMI to ask whether the identified
list of differentially abundant taxa is enriched for any dis-
ease processes or interactions. Such an approach is similar
to how the Gene Ontology (GO) has been used to support
data analysis, by providing prior knowledge relating to the
roles of given genes in realizing given functions, knowledge
which can then be used to support gene enrichment and
other data analysis [56]. Such a strategy has its advantages
over alternatives such as simply using relational database
representations, since the ontology-based approach sup-
ports better standardization, flexibility, interoperability, ma-
chine interpretation, and extensible tool development.
A newly funded project is to apply OHMI to study the
host-microbe interactions related to gastric cancer. Gas-
tric cancer (GC) is the fifth most prevalent malignancy
and the third leading cause of cancer death worldwide.
Almost half of new cases occur in China, and it is the
second leading cause of cancer death in China. The
strongest risk factor for gastric cancer is chronic Helico-
bacter pylori infection. People with an H. pylori infection
have a roughly six-fold greater risk of developing gastric
cancer than uninfected people. However, not all people
Fig. 6 The hierarchy of microbes associated with RA and their profiles. The red and blue circles represent the increased and decreased profiles,
respectively. Labeled letters represent locations as follows: G – human gut, O – human oral cavity; R – human respiratory airway. Those taxonomy
terms without circle and label are used only to generate the hierarchy
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infected with H. pylori have gastric cancer, suggesting
that there are more factors and mechanisms involved in
gastric carcinogenesis which are not yet understood.
Comparative bacterial genomic analysis in patients with
or without gastric cancer allows gene-level study of
host-microbiome interactions as it relates to gastric car-
cinogenesis in humans. Clinical trials together with
multi-omics studies are being performed to further ex-
plore the mechanisms of host-microbiome interactions
leading to gastric cancer.
OHMI is an ongoing project. Future work includes
expansion of OHMI to cover more diseases such as
obesity and inflammatory bowel disease. More mo-
lecular and cellular entities and processes will be
included to better understand HMI mechanisms. Such
host-specific microbiome profiles may serve as a bio-
logical marker for specific host types or specific
health conditions. Various types of biological condi-
tions (for example associated with patient age, bio-
logical sex, genetic makeup, and environment) may
affect the outcomes of HMIs and will be systematic-
ally studied. Thus, one important outcome of OHMI
is to identify opportunities to collect microbiome data
related to pervasive exposures that cut across multiple
disease states (for example tobacco smoking and
Western versus traditional diets) and which were not
captured by the Human Microbiome project. OHMI
is expected to become an ontology-based
Fig. 7 Data mining and ontology representation of microbiome profiles at different species level between diarrhea and health controls. (a)
MicrobiomeDB data mining. (b) OHMI representation of the results
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interoperable knowledge base of host-microbiome in-
teractions, which can be used to address many tech-
nical challenges in constructing microbiome-disease
association knowledge bases [57] and thereby help to
solve fundamental scientific questions. We also wel-
come researchers interested in the topic to participate
in the community-based OHMI development and its
application to other use cases.
Conclusion
OHMI ontologically represents entities of various types
associated with HMIs and the relations among such en-
tities. Our use cases demonstrate how OHMI could be
used as a canonical platform for HMI knowledge repre-
sentation, metadata standardization, semantic querying
and data analysis.
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